India is not planning to venture into human challenge experiments for the coronavirus vaccine until the method is proven to have an established benefit according to global experience, Health Minister Harsh Vardhan said.
Human challenge trials, which have raised ethical concerns, involve exposing the participants to the virus on purpose to study the effectiveness of the vaccine. “When conducted, human challenge studies should be undertaken with abundant forethought, caution and oversight. The value of the information to be gained should clearly justify the risks to human subjects,” Vardhan added.
He said that India has robust processes in place to ensure the vaccines that successfully complete the clinical trials are safe and effective against the novel coronavirus. According to reports, the UK is planning to host such a trial on a group of volunteers in January next year.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.